-
Notifications
You must be signed in to change notification settings - Fork 4
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
Merge pull request #52 from cancervariants/delta-model
Delta model for CIViC and MOAlmanac
- Loading branch information
Showing
7 changed files
with
408 additions
and
55 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file was deleted.
Oops, something went wrong.
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Original file line number | Diff line number | Diff line change |
---|---|---|
@@ -0,0 +1,78 @@ | ||
{ | ||
"assertions": [ | ||
{ | ||
"id": 3, | ||
"context": null, | ||
"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", | ||
"disease": { | ||
"name": "Acute Lymphoid Leukemia", | ||
"oncotree_code": null, | ||
"oncotree_term": null | ||
}, | ||
"therapy_name": "Dasatinib", | ||
"therapy_type": "Targeted therapy", | ||
"clinical_significance": "sensitivity", | ||
"predictive_implication": "FDA-Approved", | ||
"feature_ids": [3], | ||
"favorable_prognosis": null, | ||
"created_on": "01/07/21", | ||
"last_updated": "2020-11-12", | ||
"submitted_by": "breardon@broadinstitute.org", | ||
"validated": true, | ||
"source_ids": [2], | ||
"variant": { | ||
"id": 3, | ||
"feature_type": "rearrangement", | ||
"rearrangement_type": "Fusion", | ||
"gene1": "BCR", | ||
"gene2": "ABL1", | ||
"locus": null, | ||
"feature": "BCR--ABL1 Fusion" | ||
}, | ||
"test update delete": "delete" | ||
} | ||
], | ||
"sources": [ | ||
{ | ||
"id": 2, | ||
"type": "FDA", | ||
"assertion_id": [2], | ||
"doi": null, | ||
"nct": null, | ||
"pmid": "None", | ||
"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", | ||
"citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020." | ||
} | ||
], | ||
"variants": [ | ||
{ | ||
"id": 3, | ||
"feature_type": "rearrangement", | ||
"rearrangement_type": "Fusion", | ||
"gene1": "BCR", | ||
"gene2": "ABL1", | ||
"locus": null, | ||
"feature": "BCR--ABL1 Fusion" | ||
}, | ||
{ | ||
"id": 296, | ||
"feature_type": "somatic_variant", | ||
"gene": "EZH2", | ||
"chromosome": "7", | ||
"start_position": "148508728.0", | ||
"end_position": "148508728.0", | ||
"reference_allele": "A", | ||
"alternate_allele": "T", | ||
"cdna_change": "c.1936T>A", | ||
"protein_change": "p.Y646N", | ||
"variant_annotation": "Missense", | ||
"exon": "16.0", | ||
"rsid": null, | ||
"feature": "EZH2 p.Y646N (Missense)" | ||
}, | ||
{ | ||
"id": 5, | ||
"feature_type": "test_removal" | ||
} | ||
] | ||
} |
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Original file line number | Diff line number | Diff line change |
---|---|---|
@@ -0,0 +1,83 @@ | ||
{ | ||
"assertions": [ | ||
{ | ||
"id": 3, | ||
"context": null, | ||
"description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", | ||
"disease": { | ||
"name": "Acute Lymphoid Leukemia", | ||
"oncotree_code": "ALL", | ||
"oncotree_term": "Acute Lymphoid Leukemia" | ||
}, | ||
"therapy_name": "Dasatinib", | ||
"therapy_type": "Targeted therapy", | ||
"clinical_significance": "sensitivity", | ||
"predictive_implication": "FDA-Approved", | ||
"feature_ids": [3], | ||
"favorable_prognosis": null, | ||
"created_on": "01/16/21", | ||
"last_updated": "2020-11-12", | ||
"submitted_by": "breardon@broadinstitute.org", | ||
"validated": true, | ||
"source_ids": [2], | ||
"variant": { | ||
"id": 3, | ||
"feature_type": "rearrangement", | ||
"rearrangement_type": "Fusion", | ||
"gene1": "BCR", | ||
"gene2": "ABL1", | ||
"locus": null, | ||
"feature": "BCR--ABL1 Fusion" | ||
} | ||
} | ||
], | ||
"sources": [ | ||
{ | ||
"id": 2, | ||
"type": "FDA", | ||
"assertion_id": [2, 3], | ||
"doi": null, | ||
"nct": null, | ||
"pmid": "None", | ||
"url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", | ||
"citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020." | ||
}, | ||
{ | ||
"id": 22, | ||
"type": "Journal", | ||
"assertion_id": [30, 288], | ||
"doi": "10.1371/journal.pgen.1004135", | ||
"nct": null, | ||
"pmid": "24550739", | ||
"url": "https://doi.org/10.1371/journal.pgen.1004135", | ||
"citation": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135." | ||
} | ||
], | ||
"variants": [ | ||
{ | ||
"id": 3, | ||
"feature_type": "rearrangement", | ||
"rearrangement_type": "Fusion", | ||
"gene1": "BCR", | ||
"gene2": "ABL1", | ||
"locus": null, | ||
"feature": "BCR--ABL1 Fusion" | ||
}, | ||
{ | ||
"id": 296, | ||
"feature_type": "somatic_variant", | ||
"gene": "EZH2", | ||
"chromosome": "7", | ||
"start_position": "148508728.0", | ||
"end_position": "148508728.0", | ||
"reference_allele": "A", | ||
"alternate_allele": "T", | ||
"cdna_change": "c.1936T>A", | ||
"protein_change": "p.Y646N", | ||
"variant_annotation": "Missense", | ||
"exon": "16.0", | ||
"rsid": null, | ||
"feature": "EZH2 p.Y646N (Missense)" | ||
} | ||
] | ||
} |
Oops, something went wrong.